| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
|
N Engl J Med
|
2008
|
9.33
|
|
2
|
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.
|
Nat Genet
|
2013
|
6.19
|
|
3
|
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
|
Gastroenterology
|
2008
|
6.15
|
|
4
|
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.
|
Gastroenterology
|
2008
|
5.45
|
|
5
|
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
|
Gastroenterology
|
2009
|
4.90
|
|
6
|
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
|
Gastroenterology
|
2004
|
4.27
|
|
7
|
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
|
Hepatology
|
2009
|
3.50
|
|
8
|
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.
|
Drug Saf
|
2009
|
3.48
|
|
9
|
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
|
Control Clin Trials
|
2004
|
3.46
|
|
10
|
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate.
|
Circ Res
|
2008
|
3.36
|
|
11
|
Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
|
Hepatology
|
2010
|
3.35
|
|
12
|
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.
|
Clin Gastroenterol Hepatol
|
2010
|
2.96
|
|
13
|
Recommendations for the diagnosis and treatment of the acute porphyrias.
|
Ann Intern Med
|
2005
|
2.95
|
|
14
|
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.
|
J Hepatol
|
2005
|
2.63
|
|
15
|
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis.
|
Hepatology
|
2012
|
2.61
|
|
16
|
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
|
Gastroenterology
|
2010
|
2.47
|
|
17
|
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
|
Hepatology
|
2008
|
2.44
|
|
18
|
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin.
|
FASEB J
|
2006
|
2.16
|
|
19
|
Hepatitis C, porphyria cutanea tarda and liver iron: an update.
|
Liver Int
|
2012
|
2.10
|
|
20
|
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
|
Hepatology
|
2006
|
2.06
|
|
21
|
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.
|
Hepatology
|
2008
|
2.02
|
|
22
|
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis).
|
Ann Intern Med
|
2006
|
1.95
|
|
23
|
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.
|
Hepatology
|
2005
|
1.93
|
|
24
|
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network.
|
Hepatology
|
2014
|
1.83
|
|
25
|
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.
|
Hepatology
|
2013
|
1.81
|
|
26
|
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
Gastroenterology
|
2009
|
1.80
|
|
27
|
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
|
Gut
|
2010
|
1.78
|
|
28
|
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
|
Gastroenterology
|
2006
|
1.76
|
|
29
|
Liver transplantation for erythropoietic protoporphyria liver disease.
|
Liver Transpl
|
2005
|
1.76
|
|
30
|
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review.
|
Hepatology
|
2010
|
1.71
|
|
31
|
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.
|
J Hepatol
|
2008
|
1.71
|
|
32
|
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
Clin Gastroenterol Hepatol
|
2007
|
1.71
|
|
33
|
Hereditary hemochromatosis: time for targeted screening.
|
Ann Intern Med
|
2008
|
1.60
|
|
34
|
Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes.
|
Gastroenterology
|
2007
|
1.59
|
|
35
|
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
Hepatology
|
2009
|
1.46
|
|
36
|
MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins.
|
Hepatology
|
2010
|
1.38
|
|
37
|
Drug-induced liver injury associated with statins.
|
Semin Liver Dis
|
2009
|
1.36
|
|
38
|
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.
|
Gastroenterology
|
2009
|
1.35
|
|
39
|
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
|
Hepatology
|
2011
|
1.33
|
|
40
|
Catechins in dietary supplements and hepatotoxicity.
|
Dig Dis Sci
|
2013
|
1.31
|
|
41
|
Iron in nonhemochromatotic liver disorders.
|
Semin Liver Dis
|
2005
|
1.25
|
|
42
|
Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAS.
|
J Biol Chem
|
2004
|
1.22
|
|
43
|
Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection.
|
Hepatol Res
|
2007
|
1.20
|
|
44
|
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
|
J Infect Dis
|
2006
|
1.19
|
|
45
|
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.
|
Hepatology
|
2014
|
1.19
|
|
46
|
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
|
Hepatology
|
2009
|
1.18
|
|
47
|
microRNAs: fad or future of liver disease.
|
World J Gastroenterol
|
2011
|
1.15
|
|
48
|
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
|
Hepatology
|
2006
|
1.13
|
|
49
|
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
Hepatology
|
2010
|
1.12
|
|
50
|
Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.
|
Clin Gastroenterol Hepatol
|
2013
|
1.10
|
|
51
|
HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells.
|
J Hepatol
|
2006
|
1.10
|
|
52
|
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.
|
Hepatology
|
2009
|
1.08
|
|
53
|
The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes.
|
Biochim Biophys Acta
|
2012
|
1.08
|
|
54
|
Autoimmune hepatitis triggered by statins.
|
J Clin Gastroenterol
|
2006
|
1.06
|
|
55
|
Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells.
|
Liver Int
|
2008
|
1.05
|
|
56
|
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C.
|
Hepatology
|
2005
|
1.05
|
|
57
|
The diagnosis and management of erythropoietic protoporphyria.
|
Gastroenterol Hepatol (N Y)
|
2008
|
1.04
|
|
58
|
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.
|
PLoS One
|
2011
|
1.04
|
|
59
|
Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.
|
Mol Med
|
2013
|
1.03
|
|
60
|
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
|
Gastroenterology
|
2009
|
1.03
|
|
61
|
Novel role of nuclear receptor Rev-erbα in hepatic stellate cell activation: potential therapeutic target for liver injury.
|
Hepatology
|
2014
|
1.02
|
|
62
|
Hepatic porphyrias: diagnosis and management.
|
Clin Liver Dis
|
2004
|
1.00
|
|
63
|
Fatal air and bile embolism after percutaneous liver biopsy and ERCP.
|
Gastrointest Endosc
|
2005
|
1.00
|
|
64
|
Lon peptidase 1 (LONP1)-dependent breakdown of mitochondrial 5-aminolevulinic acid synthase protein by heme in human liver cells.
|
J Biol Chem
|
2011
|
0.99
|
|
65
|
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
|
Clin Gastroenterol Hepatol
|
2008
|
0.98
|
|
66
|
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
|
Hepatology
|
2011
|
0.98
|
|
67
|
Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern.
|
J Hepatol
|
2006
|
0.97
|
|
68
|
CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA.
|
J Clin Virol
|
2009
|
0.97
|
|
69
|
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
|
Clin Gastroenterol Hepatol
|
2008
|
0.96
|
|
70
|
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.
|
Gastroenterology
|
2011
|
0.95
|
|
71
|
Structural analysis of heme proteins: implications for design and prediction.
|
BMC Struct Biol
|
2011
|
0.95
|
|
72
|
Hemochromatosis mutations in Iranians with hepatitis B virus infection.
|
Clin Infect Dis
|
2004
|
0.95
|
|
73
|
The neuromediator glutamate, through specific substrate interactions, enhances mitochondrial ATP production and reactive oxygen species generation in nonsynaptic brain mitochondria.
|
J Biol Chem
|
2009
|
0.95
|
|
74
|
Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy.
|
World J Gastroenterol
|
2013
|
0.95
|
|
75
|
Intestinal expression of genes involved in iron absorption in humans.
|
Am J Physiol Gastrointest Liver Physiol
|
2002
|
0.93
|
|
76
|
Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor Bach1 and up-regulates HO-1.
|
Biochim Biophys Acta
|
2008
|
0.93
|
|
77
|
Genetic aspects of porphyria cutanea tarda.
|
Semin Liver Dis
|
2007
|
0.93
|
|
78
|
Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus.
|
Liver Int
|
2010
|
0.91
|
|
79
|
Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin.
|
Mol Cell Biochem
|
2008
|
0.91
|
|
80
|
Iron as a comorbid factor in chronic viral hepatitis.
|
Am J Gastroenterol
|
2002
|
0.90
|
|
81
|
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C.
|
Clin Gastroenterol Hepatol
|
2011
|
0.90
|
|
82
|
Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells.
|
Gastroenterology
|
2009
|
0.90
|
|
83
|
Mapping of the chick heme oxygenase-1 proximal promoter for responsiveness to metalloporphyrins.
|
Arch Biochem Biophys
|
2002
|
0.88
|
|
84
|
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
|
Hepatology
|
2010
|
0.88
|
|
85
|
Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane.
|
Br J Pharmacol
|
2003
|
0.88
|
|
86
|
A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment.
|
Psychosomatics
|
2010
|
0.88
|
|
87
|
Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials.
|
Dig Dis Sci
|
2007
|
0.88
|
|
88
|
Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.
|
Dig Dis Sci
|
2013
|
0.86
|
|
89
|
Subcellular tissue proteomics of hepatocellular carcinoma for molecular signature discovery.
|
J Proteome Res
|
2011
|
0.86
|
|
90
|
Hemochromatosis and porphyria.
|
Semin Gastrointest Dis
|
2002
|
0.86
|
|
91
|
DNA methylation patterns in alcoholics and family controls.
|
World J Gastrointest Oncol
|
2012
|
0.84
|
|
92
|
Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey.
|
Clin Infect Dis
|
2005
|
0.84
|
|
93
|
Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes.
|
PLoS One
|
2011
|
0.84
|
|
94
|
Identification of key elements that are responsible for heme-mediated induction of the avian heme oxygenase-1 gene.
|
Biochim Biophys Acta
|
2004
|
0.84
|
|
95
|
Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH.
|
Biochem J
|
2005
|
0.84
|
|
96
|
Tissue-specific expression of ALA synthase-1 and heme oxygenase-1 and their expression in livers of rats chronically exposed to ethanol.
|
FEBS Lett
|
2008
|
0.83
|
|
97
|
Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation.
|
Transplantation
|
2002
|
0.83
|
|
98
|
Discovery of putative pancreatic cancer biomarkers using subcellular proteomics.
|
J Proteomics
|
2010
|
0.83
|
|
99
|
Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV.
|
World J Gastroenterol
|
2011
|
0.83
|
|
100
|
Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method.
|
Clin Chim Acta
|
2011
|
0.82
|
|
101
|
Circadian rhythms in acute intermittent porphyria--a pilot study.
|
Eur J Clin Invest
|
2013
|
0.82
|
|
102
|
Reconstitution of hematin for intravenous infusion.
|
Ann Intern Med
|
2006
|
0.82
|
|
103
|
Respiration and ROS production in brain and spinal cord mitochondria of transgenic rats with mutant G93a Cu/Zn-superoxide dismutase gene.
|
Neurobiol Dis
|
2011
|
0.82
|
|
104
|
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis.
|
Virol J
|
2005
|
0.81
|
|
105
|
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
|
Hepatology
|
2009
|
0.80
|
|
106
|
Identification of differentially expressed proteins from primary versus metastatic pancreatic cancer cells using subcellular proteomics.
|
Cancer Genomics Proteomics
|
2012
|
0.80
|
|
107
|
No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C.
|
Gastroenterology
|
2005
|
0.79
|
|
108
|
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
|
Liver Int
|
2011
|
0.79
|
|
109
|
Metabolic and functional differences between brain and spinal cord mitochondria underlie different predisposition to pathology.
|
Am J Physiol Regul Integr Comp Physiol
|
2011
|
0.79
|
|
110
|
MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA.
|
Liver Int
|
2014
|
0.79
|
|
111
|
Neonatal androgenization exacerbates alcohol-induced liver injury in adult rats, an effect abrogated by estrogen.
|
PLoS One
|
2011
|
0.78
|
|
112
|
Chronic hepatitis E with neurologic manifestations and rapid progression of liver fibrosis in a liver transplant recipient.
|
Dig Dis Sci
|
2013
|
0.77
|
|
113
|
Hepatotoxicity of anti-TNF agents.
|
Dig Dis Sci
|
2014
|
0.77
|
|
114
|
Management of nonalcoholic steatohepatitis: an analytic review.
|
J Clin Gastroenterol
|
2002
|
0.77
|
|
115
|
Evolution of the intrahepatic T cell repertoire during chronic hepatitis C virus infection.
|
Viral Immunol
|
2005
|
0.76
|
|
116
|
Chinese medicine for treatment of chronic hepatitis B.
|
Chin J Integr Med
|
2012
|
0.76
|
|
117
|
Genetic variations in heme oxygenase-1 and chronic hepatitis.
|
Hepatology
|
2010
|
0.76
|
|
118
|
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer.
|
Proteomics
|
2013
|
0.76
|
|
119
|
Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.
|
Am J Gastroenterol
|
2010
|
0.76
|
|
120
|
Marked hyperbilirubinemia associated with the heme oxygenase-1 gene promoter microsatellite polymorphism in a boy with autoimmune hemolytic anemia.
|
Pediatrics
|
2007
|
0.76
|
|
121
|
Indications for liver transplant and AASLD guidelines.
|
Hepatology
|
2014
|
0.75
|
|
122
|
Optimal management of nonalcoholic fatty liver/steatohepatitis.
|
J Clin Gastroenterol
|
2003
|
0.75
|
|
123
|
Risk factors for porphyria cutanea tarda -the iron/HFE connection.
|
Liver Int
|
2012
|
0.75
|
|
124
|
Cytoskeletal proteins: shaping progression of hepatitis C virus-induced liver disease.
|
Int Rev Cell Mol Biol
|
2013
|
0.75
|